Axon 1992
CAS [919486-40-1]
MF C20H20ClN5O2MW 397.86
Potent and selective STAT6 inhibitor (IC50: 21 nM)
KEYWORDS:AS 1517499 | supplier | STAT6 inhibitor | AS1517499 | AS-1517499 | CAS [919486-40-1] | DNA-RNA | STAT6 | Inhibitor | Transcription Factor | NF-κB | IL-13 | TNF-α | asthma | interleukin
S Nagashima et al. Synthesis and evaluation of 2-{[2-(4-hydroxyphenyl)-ethyl]amino}pyrimidine-5-carboxamide derivatives as novel STAT6 inhibitors. Bioorg. Med. Chem. 2007, 15(2), 1044-1055. |
Y Chiba et al. A novel STAT6 inhibitor AS1517499 ameliorates antigen-induced bronchial hypercontractility in mice. Am. J. Respir. Cell Mol. Biol. 2009, 41(5), 516-524. |
K Goto et al. The proximal STAT6 and NF-κB sites are responsible for IL-13- and TNF-α-induced RhoA transcriptions in human bronchial smooth muscle cells. Pharmacol. Res. 2010, 61(5), 466–472. |
List of publications using AS 1517499 (Axon 1992) purchased from Axon Medchem
4-(benzylamino)-2-(3-chloro-4-hydroxyphenethylamino)pyrimidine-5-carboxamide
[919486-40-1]
Axon Medchem的业务之一,是独有的Axon Ligands配体库,在世界范围内,被认为是药物研发的标准。这其中,针对850余种生物靶标(包括细胞信号、基因转录、凋亡、细胞周期调控、CNS等),Axon Medchem拥有多达2000余种小分子抑制剂或调节剂。除了配体库,Axon Medchem还是欧洲著名的CRO公司,主要针对生物活性分子和药物类似分子展开合成及协议开发工作,在过去的10年中,Axon Medchem已经发现了多种潜在药物分子,并在生物医药界享有一定的声誉。